Skip to main content
NCBI home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2010 Feb 26;11(3):259–265. doi: 10.1007/s10194-010-0194-3

Focus on therapy: hemicrania continua and new daily persistent headache

Paolo Rossi 1, Cristina Tassorelli 2,✉, Marta Allena 2, Enrico Ferrante 3, Carlo Lisotto 4, Giuseppe Nappi 2,5
PMCID: PMC3451920  PMID: 20186563

Abstract

Hemicrania continua (HC) and new daily-persistent headache (NDPH) represent the only two forms of chronic daily headache in Chap. IV “Other Primary Headaches” of the second edition of the International Classification of Headache Disorders. HC and NDPH are rare and poorly defined from a pathophysiological point of view; as a consequence, their management is largely empirical. Indeed, there is a lack of prospective, controlled trials in this field, and treatment effectiveness is basically inferred from the results of sparse open-label trials, retrospective case series, clinical experience and expert opinions. In this narrative review we have summarised the information collected from an extensive analysis of the literature on the treatment of HC and NDPH in order to provide the best available and up-to-date evidence for the management of these two rare forms of primary headache. Indomethacin is the mainstay of HC management. The reported effective dose of indomethacin ranges from 50 to 300 mg/day. Gabapentin 600–3,600 mg tid, topiramate 100 mg bid, and celecoxib 200–400 mg represent the most interesting alternative choices in the patients who do not tolerate indomethacin or who have contraindications to its use. NDPH is very difficult to treat and it responds poorly only to first-line options used for migraine or tension-type headache.

Keywords: Hemicrania continua, New daily persistent headache, Chronic daily headache, Therapy, Management

Full Text

The Full Text of this article is available as a PDF (207.2 KB).

Acknowledgments

Conflict of interest

None.

References

  • 1.International Headache Society Classification Subcommittee (2004) International classification of headache disorders, 2nd edn. Cephalalgia 24 (Suppl 1):1–60 [DOI] [PubMed]
  • 2.Evers S, Frese A, May A, Sixt G, Straube A. Die therapie seltener idiopatischer Kopfschmerzerkrankungen – Empfehlungen der Deutschen Migrane und Kopfschmerzgesellschaft. http://www.dmkg.de/pdf/selt_idiop_ks.pdf. Accessed 12 Jan 2010
  • 3.Sjaastad O, Spierings EL. “Hemicrania continua”: another headache absolutely responsive to indomethacin. Cephalalgia. 1984;4:65–70. doi: 10.1046/j.1468-2982.1984.0401065.x. [DOI] [PubMed] [Google Scholar]
  • 4.Peres MF, Silberstein SD, Nahmias S, Schechter AL, Youssef I, Rozen TD, Young WB. Hemicrania continua is not that rare. Neurology. 2001;57:948–951. doi: 10.1212/wnl.57.6.948. [DOI] [PubMed] [Google Scholar]
  • 5.Sjaastad O, Bakketeig LS. The rare, unilateral headaches. Vågå study of headache epidemiology. J Headache Pain. 2007;8:19–27. doi: 10.1007/s10194-006-0292-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pareja JA, Vincent M, Antonaci F, Sjaastad O. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia. 2001;21:874–877. doi: 10.1046/j.1468-2982.2001.00276.x. [DOI] [PubMed] [Google Scholar]
  • 7.Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain. 1997;120:193–209. doi: 10.1093/brain/120.1.193. [DOI] [PubMed] [Google Scholar]
  • 8.Murmura MJ, Silberstein SD, Gupta M. Hemicrania continua: who responds to indomethacin? Cephalalgia. 2008;29:300–307. doi: 10.1111/j.1468-2982.2008.01719.x. [DOI] [PubMed] [Google Scholar]
  • 9.Allena M, Tassorelli C, Sances G, Guaschino E, Sandrini G, Nappi G, Antonaci F (2008) Is hemicrania continua a single entity or the association of two headache forms? Considerations from a case report. Headache Oct 10 (Epub ahead of print) [DOI] [PubMed]
  • 10.Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache. 2004;44:747–761. doi: 10.1111/j.1526-4610.2004.04141.x. [DOI] [PubMed] [Google Scholar]
  • 11.Spierings EL, Sjaastad O. Hemicrania continua is not that rare. Neurology. 2002;59:476–477. doi: 10.1212/wnl.59.3.476-a. [DOI] [PubMed] [Google Scholar]
  • 12.Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the “indotest”. Headache. 1998;38:122–128. doi: 10.1046/j.1526-4610.1998.3802122.x. [DOI] [PubMed] [Google Scholar]
  • 13.Baldacci F, Nuti A, Cafforio G, Lucetti C, Logi C, Cipriani G, Orlandi G, Bonuccelli U. ‘INDOTEST’ in atypical hemicrania continua. Cephalalgia. 2008;28:300–301. doi: 10.1111/j.1468-2982.2007.01525.x. [DOI] [PubMed] [Google Scholar]
  • 14.Pareja JA, Caminero AB, Franco E, Casado JL, Pascual J, Sánchez del Río M. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia. 2001;21:906–910. doi: 10.1046/j.1468-2982.2001.00287.x. [DOI] [PubMed] [Google Scholar]
  • 15.Dodick D. Indomethacin-responsive headache syndromes. Curr Pain Headache Rep. 2004;8:19–26. doi: 10.1007/s11916-004-0036-6. [DOI] [PubMed] [Google Scholar]
  • 16.Sjaastad O. Chronic paroxysmal hemicrania, hemicrania continua and SUNCT: the fate of the three-first described cases. J Headache Pain. 2006;7:151–156. doi: 10.1007/s10194-006-0303-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sjaastad O, Antonaci F. A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Headache. 1995;35:549–550. doi: 10.1111/j.1526-4610.1995.hed3509549.x. [DOI] [PubMed] [Google Scholar]
  • 18.Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache. 2002;42:530–531. doi: 10.1046/j.1526-4610.2002.02131.x. [DOI] [PubMed] [Google Scholar]
  • 19.Peres MF, Zukerman E. Hemicrania continua responsive to rofecoxib. Cephalalgia. 2000;20:130–131. doi: 10.1046/j.1468-2982.2000.00029.x. [DOI] [PubMed] [Google Scholar]
  • 20.Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ. 2005;330:440. doi: 10.1136/bmj.330.7489.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Roumie CL, Choma NN, Kaltenbacch L, Mitchel EF, Jr, Arbogast PG, Mr Griffin. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute yocardial infarction, and death from coronary hearth disease. Pharmacoepidemiol Drug Saf. 2009;18:1053–1063. doi: 10.1002/pds.1820. [DOI] [PubMed] [Google Scholar]
  • 22.Rozen TD. Melatonin responsive hemicrania continua. Headache. 2006;46:1203–1204. doi: 10.1111/j.1526-4610.2006.00514_1.x. [DOI] [PubMed] [Google Scholar]
  • 23.Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache. 2006;46:524–527. doi: 10.1111/j.1526-4610.2006.00386_5.x. [DOI] [PubMed] [Google Scholar]
  • 24.Matharu MS, Bradbury P, Swash M. Hemicrania continua: side alternation and response to topiramate. Cephalalgia. 2006;26:341–344. doi: 10.1111/j.1468-2982.2005.01034.x. [DOI] [PubMed] [Google Scholar]
  • 25.Brighina F, Palermo A, Cosentino G, Fierro B. Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate. Headache. 2007;47:441–443. doi: 10.1111/j.1526-4610.2006.00628.x. [DOI] [PubMed] [Google Scholar]
  • 26.Camarda C, Camarda R, Monastero R. Chronic paroxysmal hemicrania and hemicrania continua responding to topiramate: two case reports. Clin Neurol Neurosurg. 2008;110:88–91. doi: 10.1016/j.clineuro.2007.09.002. [DOI] [PubMed] [Google Scholar]
  • 27.Lambru G, Castellini P, Bini A, Evangelista A, Manzoni GC, Torelli P. Hemicrania continua evolving from cluster headache responsive to valproic acid. Headache. 2008;48:1374–1376. doi: 10.1111/j.1526-4610.2008.01249.x. [DOI] [PubMed] [Google Scholar]
  • 28.Spears RC. Is gabapentin an effective treatment choice for hemicrania continua? J Headache Pain. 2009;10:271–275. doi: 10.1007/s10194-009-0126-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalalgias and hemicrania continua. Drugs. 2003;63:1637–1677. doi: 10.2165/00003495-200363160-00002. [DOI] [PubMed] [Google Scholar]
  • 30.Rajabally YA, Jacob S. Hemicrania continua responsive to verapamil. Headache. 2005;45:1082–1083. doi: 10.1111/j.1526-4610.2005.05193_1.x. [DOI] [PubMed] [Google Scholar]
  • 31.Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: lack of efficacy of sumatriptan. Headache. 1998;38:197–200. doi: 10.1046/j.1526-4610.1998.3803197.x. [DOI] [PubMed] [Google Scholar]
  • 32.Bordini C, Antonaci F, Stovner LJ, Schrader H, Sjaastad O. “Hemicrania continua”: a clinical review. Headache. 1991;31:20–26. doi: 10.1111/j.1526-4610.1991.hed3101020.x. [DOI] [PubMed] [Google Scholar]
  • 33.Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. Funct Neurol. 1997;12:11–15. [PubMed] [Google Scholar]
  • 34.Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache–long term safety and efficacy. Cephalalgia. 2007;27:153–157. doi: 10.1111/j.1468-2982.2007.01272.x. [DOI] [PubMed] [Google Scholar]
  • 35.Burns B, Watkins L, Goadsby PJ. Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study. Lancet Neurol. 2008;7:1001–1012. doi: 10.1016/S1474-4422(08)70217-5. [DOI] [PubMed] [Google Scholar]
  • 36.Rossi P, Faroni V, Tassorelli C, Nappi G. Diagnostic delay and mismanagement in a referral population with hemicrania continua. Headache. 2009;49:227–234. doi: 10.1111/j.1526-4610.2008.01260.x. [DOI] [PubMed] [Google Scholar]
  • 37.Pareja JA, Antonaci F, Vincent M. The hemicrania continua diagnosis. Cephalalgia. 2001;21:940–946. doi: 10.1046/j.1468-2982.2001.00290.x. [DOI] [PubMed] [Google Scholar]
  • 38.Diaz-Mitoma F, Vanast WJ, Tyrrel DL. Increased frequency of Epstein–Barr virus excretion in patients with new-daily persistent headaches. Lancet. 1987;1:411–415. doi: 10.1016/S0140-6736(87)90119-X. [DOI] [PubMed] [Google Scholar]
  • 39.Vanast WJ. New daily persistent headache: definition of a benign syndrome. Headache. 1986;26:317. [Google Scholar]
  • 40.Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near daily headache: proposed revision to the IHS-criteria. Headache. 1994;34:1–7. doi: 10.1111/j.1526-4610.1994.hed3401001.x. [DOI] [PubMed] [Google Scholar]
  • 41.Kung E, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. New daily persistent headache in the paediatric population. Cephalalgia. 2009;29:17–22. doi: 10.1111/j.1468-2982.2008.01647.x. [DOI] [PubMed] [Google Scholar]
  • 42.Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22:66–69. doi: 10.1046/j.1468-2982.2002.00326.x. [DOI] [PubMed] [Google Scholar]
  • 43.Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily-persistent headache and treatment refractory chronic migraine. Headache. 2007;47:1050–1055. doi: 10.1111/j.1526-4610.2006.00722.x. [DOI] [PubMed] [Google Scholar]
  • 44.Rozen TD, Roth JM, Denenberg N. Cervical spine joint hypermobility: a possible predisposing factor for new daily persistent headache. Cephalalgia. 2006;26:1182–1185. doi: 10.1111/j.1468-2982.2006.01187.x. [DOI] [PubMed] [Google Scholar]
  • 45.Goadsby PJ, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiatry. 2002;72(Suppl 2):ii6–ii9. doi: 10.1136/jnnp.72.suppl_2.ii6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24:955–959. doi: 10.1111/j.1468-2982.2004.00771.x. [DOI] [PubMed] [Google Scholar]
  • 47.Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study. Neurol Sci. 2004;25(Suppl 3):S281–S282. doi: 10.1007/s10072-004-0310-8. [DOI] [PubMed] [Google Scholar]
  • 48.Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache. 2001;41:830–832. doi: 10.1046/j.1526-4610.2001.01152.x. [DOI] [PubMed] [Google Scholar]
  • 49.Marmura MJ, Passero FC, Jr, Young WB. Mexiletine for refractory chronic headache: a report of nine cases. Headache. 2008;48:1506–1510. doi: 10.1111/j.1526-4610.2008.01234.x. [DOI] [PubMed] [Google Scholar]
  • 50.Spears RC. Efficacy of botulinum toxin type A in new daily persistent headache. J Headache Pain. 2008;9:405–406. doi: 10.1007/s10194-008-0078-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES